Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
FDA keurt pembrolizumab goed voor adjuvante behandeling stadium IIB/IIC-melanoom
dec 2021 | Dermato-oncologie, Immuuntherapie